MarketCap
Facebook
X
Telegram
T2 Biosystems Net Income | TTOO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.1 M | -62 M | -49.2 M | -46.8 M | -59 M | -15.1 M | -62.4 M | -54.8 M | -45.3 M | -31.4 M | -20.6 M | -14.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.5 M | -62.4 M | -42.6 M |
Quarterly Net Income T2 Biosystems
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.1 M | -8.96 M | -13.5 M | - | -15.4 M | -6.35 M | -18 M | - | -17.4 M | -18 M | -16.5 M | - | -14 M | -12.5 M | -10.7 M | - | -11.3 M | -10.7 M | -14.9 M | -14 M | -14.2 M | -15.6 M | -15.1 M | -15.1 M | -10.8 M | -12.3 M | -12.9 M | -18.2 M | -14.1 M | -15.5 M | -14.7 M | -14.5 M | -12.8 M | -14 M | -13.4 M | -12 M | -11.6 M | -11 M | -10.6 M | -9.08 M | -8.09 M | -7.3 M | -6.92 M | -6.37 M | -4.64 M | -5.01 M | -4.58 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.58 M | -18.2 M | -12.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.14 | 1.9 % | $ 4.92 M | USA |
 |
BioNano Genomics
BNGO
|
-26.4 M | $ 1.17 | 0.88 % | $ 6.37 M | USA |
 |
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B |  Niderland |
 |
Centogene N.V.
CNTG
|
-35.5 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 1.21 | 0.79 % | $ 1.61 M | USA |
 |
Aspira Women's Health
AWH
|
-12.8 K | - | -6.19 % | $ 10.5 M | USA |
 |
Brainsway Ltd.
BWAY
|
2.92 M | $ 14.3 | 0.7 % | $ 486 M |  Israel |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 242.76 | 0.02 % | $ 26.9 B | USA |
 |
Celcuity
CELC
|
-177 M | $ 88.44 | 3.05 % | $ 4.14 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 291.5 | 0.16 % | $ 14.4 B | USA |
 |
Check-Cap Ltd.
CHEK
|
4.14 M | - | - | $ 9.42 M | Israel |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-12 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-811 M | - | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-41.7 M | $ 6.77 | 1.18 % | $ 27 M | Israel |
 |
DexCom
DXCM
|
836 M | $ 90.82 | 1.71 % | $ 35.4 B | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Soleno Therapeutics
SLNO
|
20.9 M | - | - | $ 2.69 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 398.58 | 0.64 % | $ 28.8 B |  Schweiz |
 |
Psychemedics Corporation
PMD
|
-1.86 M | - | -1.84 % | $ 15.3 M | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 3.16 | 1.92 % | $ 293 M | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
ENDRA Life Sciences
NDRA
|
-7.03 M | $ 5.01 | 4.53 % | $ 3.94 M | USA |
 |
NeoGenomics
NEO
|
-108 M | $ 18.05 | 7.31 % | $ 2.31 B | USA |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
-13.8 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
23.6 M | - | -16.95 % | $ 1.54 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 21.85 | 0.27 % | $ 489 M | USA |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 3.48 | 1.11 % | $ 113 K | USA |
 |
PerkinElmer
PKI
|
241 M | - | -0.91 % | $ 14.7 B | USA |
 |
Meridian Bioscience
VIVO
|
42.5 M | - | - | $ 1.49 B | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.4 | 0.32 % | $ 420 M | USA |
 |
Quotient Limited
QTNT
|
-125 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 170.02 | 0.18 % | $ 13.3 B |  Irlanda |
 |
Renalytix AI plc
RNLX
|
-33.5 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Interpace Biosciences
IDXG
|
24.6 M | $ 1.45 | 2.11 % | $ 6.41 M | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 261.75 | 0.05 % | $ 45 B | USA |
 |
Surmodics
SRDX
|
-11.5 M | - | - | $ 608 M | USA |